Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.

Abstract

OBJECTIVE:

Characterize potential risk factors and the relationship of dopamine agonist (DA) withdrawal syndrome (DAWS), dopamine dysregulation syndrome (DDS), and impulse control disorders (ICDs) in Parkinson's disease (PD).

METHODS:

A retrospective chart review categorized cases into three groups: DAWS, DDS, and ICDs.

RESULTS:

A total of 1,040 subjects met inclusion criteria. There were 332 subjects with a history of tapering DAs and 26 (7.8%) developed DAWS. Fourteen (1.3%) and 89 (8.6%) met the criteria for both DDS and ICD. Subjects with DAWS, DDS, and ICDs had a higher baseline dose of DA, levodopa, and total dopaminergic medication (p < .05), compared to those without the three conditions. DDS was found to be related to the DAWS group (p < .001). When comparing to the PD population without DDS, younger age at onset of PD (p = .027), presence of DAWS (p < .001), ICDs (p = .003), and punding (p = .042) were all correlated with the DDS group, while male sex (p = .045), younger age at onset of PD (p < .001), presence of DAWS (p < .001), and presence of DDS (p = .001) and punding (p < .001) were related to the ICD group.

CONCLUSIONS:

There was a strong relationship between DAWS, DDS, and ICD in this large PD cohort. Dopaminergic therapy in a subset of PD patients was strongly associated with addiction-like behavioral issues.

• Authors: Natlada Limotai, Genko Oyama, Criscely Go, Oscar Bernal, Tiara Ong, Sarah J Moum, Roongroj Bhidayasiri, Kelly D Foote, Dawn Bowers, Herbert Ward, Michael S Okun
• Journal: The International journal of neuroscience (Int J Neurosci) Vol. 122 Issue 3 Pg. 145-53 (Mar 2012) ISSN: 1563-5279 [Electronic] England
• PMID: 22023411 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antiparkinson Agents
• Dopamine Agonists

Topics

• Age of Onset
• Aged
• Aged, 80 and over
• Antiparkinson Agents (adverse effects, blood)
• Cohort Studies
• Comorbidity
• Disruptive, Impulse Control, and Conduct Disorders (chemically induced, epidemiology, physiopathology)
• Dopamine Agonists (adverse effects, blood)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Parkinson Disease (drug therapy, epidemiology, physiopathology)
• Retrospective Studies
• Sex Distribution
• Substance Withdrawal Syndrome (epidemiology, physiopathology)
• Substance-Related Disorders (epidemiology, physiopathology)